Das Guillain-Barré-Syndrom

Das Guillain-Barré-Syndrom (GBS) ist der Prototyp einer akut verlaufenden autoimmun vermittelten entzündlichen Polyradikuloneuritis. Das wichtigste zusatzdiagnostische Verfahren stellt die Elektroneurografie dar. In diesem CME-Artikel sollen wesentliche Aspekte der klinischen Symptomatik, der Diagnostik und der Therapie dieses Krankheitsbildes zusammengefasst werden, mit Fokus auf elektrophysiologische Veränderungen und rezente Ergebnisse multizentrischer Kohortenuntersuchungen.

Abstract

The Guillain-Barré Syndrome (GBS) is the prototype of an acute autoimmune-mediated inflammatory polyradiculoneuritis. The most important auxiliary diagnostic method is electroneurography. This CME article aims to summarize key aspects of the clinical symptomatology, diagnostics, and therapy of this condition, with a focus on electrophysiological changes and recent findings from multicenter cohort studies.

Schlüsselwörter

Guillain-Barré-Syndrom - Elektroneurografie - Immuntherapie

Key words

Guillain-Barré Syndrome (GBS) - Nerve Conduction Studies (NCS) - Immunotherapy

Publication History

Article published online:
01 September 2025

• Literatur

• 1 Sejvar JJ, Baughman AL, Wise M. et al. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011; 36: 123-133
• 2 Xu L, Zhao C, Bao Y. et al. Variation in worldwide incidence of Guillain-Barré syndrome: a population-based study in urban China and existing global evidence. Front Immunol 2024; 15: 1415986
• 3 Lehmann HC, Köhne A, Meyer zu Hörste G. et al. Incidence of Guillain-Barré syndrome in Germany. J Peripher Nerv Syst 2007; 12: 285
• 4 Doets AY, Verboon C, van den Berg B. et al. Regional variation of Guillain-Barré syndrome. Brain 2018; 141: 2866-2877
• 5 Uncini A, Susuki K, Yuki N. Nodo-paranodopathy: beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies. Clin Neurophysiol 2013; 124: 1928-1934
• 6 Fortanier E, Berling E, Zanin A. et al. How to distinguish Guillain-Barré syndrome from nitrous oxide-induced neuropathy: a 2-year, multicentric, retrospective study. Eur J Neurol 2023; 30: 3296-3306
• 7 Al-Hakem H, Doets AY, Stino AM. et al. CSF findings in relation to clinical characteristics, subtype, and disease course in patients with Guillain-Barré syndrome. Neurology 2023; 100: e2386-e2397
• 8 Fokke C, van den Berg B, Drenthen J. et al. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain 2014; 137: 33-43
• 9 van Doorn PA, Van den Bergh PYK, Hadden RDM. et al. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome. J Peripher Nerv Syst 2023; 28: 535-563
• 10 Hadden RD, Cornblath DR, Hughes RA. et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol. 1998; 44: 780-788
• 11 Rajabally YA, Durand MC, Mitchell J. et al. Electrophysiological diagnosis of Guillain-Barré syndrome subtype: could a single study suffice?. J Neurol Neurosurg Psychiatry 2015; 86: 115-119
• 12 Gordon PH, Wilbourn AJ. Early electrodiagnostic findings in Guillain-Barré syndrome. Arch Neurol 2001; 58: 913-917
• 13 Berciano J, Orizaola P, Gallardo E. et al. Very early Guillain-Barré syndrome: a clinical-electrophysiological and ultrasonographic study. Clin Neurophysiol Pract 2019; 5: 1-9
• 14 Veltsista D, Kefalopoulou Z, Kintos V. et al. Identical late motor responses in early Guillain-Barré syndrome: a-waves and repeater F-waves. J Peripher Nerv Syst 2023; 28: 41-46
• 15 John T, Mathew AE. Utilizing nerve conduction studies to identify very early Guillain-Barré syndrome and distinguish it from mimics in emergency settings. Muscle Nerve 2024; 70: 929-936
• 16 Kuwabara S, Yuki N, Koga M. et al. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome. Ann Neurol 1998; 44: 202-208
• 17 Susuki K, Rasband MN, Tohyama K. et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 2007; 27: 3956-3967
• 18 Uncini A. Autoimmune nodo-paranodopathies 10 years later: clinical features, pathophysiology and treatment. J Peripher Nerv Syst 2023; 28 Suppl 3 S23-S35
• 19 Guémy C, Durand MC, Brisset M. et al. Changes in electrophysiological findings suggestive of demyelination following Guillain-Barré syndrome: a retrospective study. Muscle Nerve 2023; 67: 394-400
• 20 Chakraborty T, Kramer CL, Wijdicks EFM. et al. Dysautonomia in Guillain-Barré Syndrome: prevalence, clinical spectrum, and outcomes. Neurocrit Care 2020; 32: 113-120
• 21 Grimm A, Décard BF, Schramm A. et al. Ultrasound and electrophysiologic findings in patients with Guillain-Barré syndrome at disease onset and over a period of six months. Clin Neurophysiol 2016; 127: 1657-1663
• 22 Lehmann HC, Hartung HP, Hetzel GR. et al. Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders. Arch Neurol 2006; 63: 1066-1071
• 23 Walgaard C, Jacobs BC, Lingsma HF. et al. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol 2021; 20: 275-283
• 24 Kuwabara S, Kusunoki S, Kuwahara M. et al. Efficacy and safety of eculizumab in Guillain-Barré syndrome: a phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial. J Peripher Nerv Syst 2024; 29: 339-349
• 25 Fisher MA. The contemporary role of F-wave studies: F-wave studies: clinical utility. Muscle Nerve 1998; 21: 1098-1101